Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026 before market open. The company will host a conference call at 8:30 a.m. Eastern Time the same day.
Dial-in details: 888-455-0391 (U.S./Canada) or 773-756-0467 (international) with passcode 7895081. The earnings release and live webcast will be posted at www.QuestDiagnostics.com/investor. Participants are advised to dial in ~10 minutes early.
A replay will be available online at the investor site and by phone at 866-388-5361 (domestic) or 203-369-0416 (international) from ~10:30 a.m. ET on February 10, 2026 until midnight ET on February 24, 2026. Investors are encouraged to review the company’s periodic SEC filings, including risk factors.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, DGX declined 0.22%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus 1 Down
DGX was down 1.29% with mixed peer moves: LH -3.06%, WAT -0.04%, MTD -0.82%, NTRA +0.52%, PKI flat. This pattern points to stock-specific rather than broad sector action.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Clinical data update | Positive | +4.0% | Haystack MRD ctDNA data highlighted at 2026 ASCO GI symposium. |
| Jan 05 | JV partnership | Positive | -0.2% | Corewell Health JV forming Diagnostic Lab of Michigan with Quest majority. |
| Dec 19 | Conference appearance | Neutral | -0.1% | Planned presentation at 44th J.P. Morgan Healthcare Conference. |
| Dec 09 | Research collaboration | Positive | -1.2% | Haystack MRD collaboration in phase II MRD-PORT trial for NSCLC. |
| Dec 01 | Strategic collaboration | Positive | -2.9% | Octave MSDA Test access via ~7,000 Quest patient service centers. |
Recent DGX headlines often read as strategically positive, but price reactions have been mixed, with several constructive collaboration updates followed by modest declines.
Over the past months, Quest Diagnostics issued multiple strategic updates. On Jan 6, 2026, ASCO GI data on the Haystack MRD test coincided with a +4.02% move. A Corewell Health joint venture on Jan 5, 2026 and an Octave MSDA collaboration on Dec 1, 2025 were followed by slight declines. A J.P. Morgan Healthcare Conference appearance on Dec 19, 2025 had minimal price impact. Against this backdrop, today’s earnings-date announcement fits a pattern of operational news with generally moderate stock reactions.
Regulatory & Risk Context
Quest Diagnostics has an effective S-3ASR automatic shelf filed on 2025-06-20, permitting issuance of debt securities on a delayed or continuous basis under Rule 415, with specific terms to be set in future prospectus supplements.
Market Pulse Summary
This announcement set February 10, 2026 as the date for Quest Diagnostics’ fourth quarter and full-year 2025 results, with a conference call at 8:30 a.m. ET. It primarily provided logistics, including dial-in numbers, passcode, and replay details, rather than new financial figures. In context of recent collaborations and conference presentations, investors may focus on how upcoming results reflect these strategic moves and any commentary on capital structure given the existing S-3ASR debt shelf.
AI-generated analysis. Not financial advice.
The conference call can be accessed by dialing 888-455-0391 within the
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers; no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on February 10, 2026 until midnight Eastern Time on February 24, 2026.
Anyone listening to the call is encouraged to read the company's periodic reports on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-to-release-fourth-quarter-and-full-year-2025-financial-results-on-february-10-2026-302655842.html
SOURCE Quest Diagnostics Incorporated
FAQ
When will Quest Diagnostics (DGX) report Q4 and full year 2025 results?
What time is the Quest Diagnostics (DGX) earnings call on February 10, 2026?
How can I join the Quest Diagnostics (DGX) Q4 2025 earnings call by phone?
Where will Quest Diagnostics (DGX) post the earnings release and webcast?
How can I access the replay of the Quest Diagnostics (DGX) February 10, 2026 call?
Should investors review Quest Diagnostics (DGX) SEC filings before the call?
